Arkolith/Insider Trading/TRAX/Form 4

Lizzul Paul F.

Chief Medical OfficerFirst Tracks Biotherapeutics, Inc. (TRAX) · full profile →Form 4 · filed Apr 22, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
0 non-derivative · 11 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 20, 2026Grant(A)84K—$084K
Apr 20, 2026Grant(A)45K—$045K
Apr 20, 2026Grant(A)70K—$070K
Apr 20, 2026Grant(A)67K—$067K
Apr 20, 2026Grant(A)116K—$0116K
Apr 20, 2026Grant(A)97K—$097K
Apr 20, 2026Grant(A)29K—$029K
Apr 20, 2026Grant(A)6K—$06K
Apr 20, 2026Grant(A)21K—$021K
Apr 20, 2026Grant(A)26K—$026K
Apr 20, 2026Grant(A)21K—$021K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001711462-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML